Aponermin-Based Bridging Therapy Prior to CAR-T Infusion in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease

This is a prospective, single-arm, multicenter, open-label study to evaluate the efficacy and safety of aponermin-based bridging therapy prior to CAR-T infusion in relapsed/refractory multiple myeloma patients with extramedullary disease.

Trial Details

NCT ID
NCT06793475
Phase
NA
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Status
RECRUITING
Cancer Type
Relapsed/Refractory Multiple Myeloma
Interventions
  • anti-BCMA/GPRC5D bispecific CAR-T
  • Apornemin
  • Carfilzomib
  • Thalidomide
  • Dexamethasone
Locations (sample)
  • Beijing, China|39.9075,116.39723
  • Tianjin, China|39.14222,117.17667

Key Eligibility Criteria

  • Be informed and voluntarily sign the Informed Consent Form (ICF).
  • Age ≥18 years.
  • Confirmed diagnosis of Multiple Myeloma(MM) (IMWG consensus guidelines)
  • Subjects with diagnosed relapsed or refractory extramedullary multiple myeloma according to IMWG criteria and have had at least 1 prior lines of th…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Relapsed/Refractory Multiple Myeloma Trials on Trialify →